Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer.
- Author:
Yang XU
1
;
Liangan CHEN
;
Qing TIAN
;
Zhen YANG
;
Wei ZHAO
;
Ping WANG
;
Xingchen LIU
;
Chunsun LI
Author Information
- Publication Type:Journal Article
- MeSH: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; drug therapy; mortality; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quinazolines; administration & dosage; therapeutic use; Receptor, Epidermal Growth Factor; antagonists & inhibitors; Retrospective Studies; Young Adult
- From: Chinese Journal of Lung Cancer 2010;13(1):48-53
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND AND OBJECTIVEEpidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been widely used as the second- and third-line therapy in patients with advanced non-small cell lung cancer (NSCLC). However, its effect in the first-line treatment is unclear. The aim of this study was to evaluate the efficacy and safety of EGFR-TKI as first-line therapy.
METHODSThe clinical characteristics, responses rate, disease control rate and overall survival were retrospectively analyzed in 77 chemonaive patients with advanced NSCLC. All of the patients received oral gefitinib (250 mg/d) or erlotinib (150 mg/d) until disease progression or unacceptable toxicity occurrence.
RESULTSThe overall response rate was 33.8% and the disease control rate was 68.8%. The median progression-free survival and the median survival time were 6.0 months and 8.9 months, respectively. One-year survival rate was 61.4%. Responses correlated significantly with histology, PS score, smoking history, skin rash, EGFR mutations and serum CEA. Histology and skin rash were the independent predictors of survival. Common toxicities were skin rash and mild diarrhea. EGFR-TKI could improve the clinical symptoms and the quality of life.
CONCLUSIONEGFR-TKI is effective and well tolerated as first-line therapy in patients with advanced NSCLC.
